Related Experiment Video

Updated: Nov 19, 2025

Integration of Bioinformatics Approaches and Experimental Validations to Understand the Role of Notch Signaling in Ovarian Cancer
09:08

Integration of Bioinformatics Approaches and Experimental Validations to Understand the Role of Notch Signaling in Ovarian Cancer

Published on: January 12, 2020

7.0K

NOTCH Activation via gp130/STAT3 Signaling Confers Resistance to Chemoradiotherapy

Kristin Koerdel1, Melanie Spitzner2, Thomas Meyer3

  • 1Institute of Cellular and Molecular Immunology, University Medical Center Goettingen, 37073 Goettingen, Germany.

Cancers
|February 3, 2021
PubMed

Insights

Blocking STAT3 signaling re-sensitizes cancer cells to chemoradiotherapy by inhibiting the NOTCH pathway. This approach abolished tumor growth in mice and may improve patient outcomes.

Area of Science:

  • Oncology
  • Molecular Biology
  • Immunology

Background:

  • Tumor resistance to chemoradiotherapy is a major clinical challenge.
  • Mechanisms driving treatment resistance are not fully understood.
  • Inflammatory pathways are implicated in cancer progression and treatment failure.

Purpose of the Study:

  • To investigate the role of STAT3 signaling in chemoradiotherapy resistance.
  • To identify molecular targets for overcoming treatment refractoriness.
  • To explore the interplay between inflammation and developmental pathways in cancer resistance.

Main Methods:

  • Blocking STAT3 signaling in cancer cells and xenograft mouse models.
  • Assessing tumor response to chemoradiotherapy.
  • Investigating the NOTCH pathway and its regulators (RBPJ, NOTCH ligands).
  • Genetic profiling of rectal cancer patient data.

Main Results:

  • Inhibition of STAT3 signaling re-sensitized treatment-refractory cancer cells to chemoradiotherapy.
  • STAT3 blockade abolished tumor growth in a xenograft mouse model when combined with chemoradiotherapy.
  • STAT3 resistance mechanism involves upregulation of RBPJ, a key NOTCH pathway regulator.
  • NOTCH pathway inhibition mimicked the effects of STAT3 blockade.
  • NOTCH expression correlated with clinical outcome in rectal cancer patients.

Conclusions:

  • STAT3 and NOTCH pathways form a critical axis mediating resistance to chemoradiotherapy.
  • This STAT3/NOTCH axis represents a novel target for overcoming treatment resistance.
  • Findings support biomarker-driven patient stratification and novel therapeutic strategies.
Keywords:
NOTCHSTAT3chemoradiotherapygastrointestinal cancertreatment resistance

More Related Videos

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.4K
Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer09:40

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

2.9K

Related Concept Videos

Role Of Notch Signalling In Intestinal Stem Cell Renewal01:12

Role Of Notch Signalling In Intestinal Stem Cell Renewal

Notch signaling was first discovered in Drosophila melanogaster, where it is involved in cell lineage differentiation. Notch signaling regulates the maintenance and differentiation of intestinal stem cells or ISCs by controlling the expression of atonal homolog 1 or Atoh1. Atoh1 directs cells to differentiate into secretory cells.
Direct cell-to-cell contact is needed for the activation of Notch signaling. The signal is initiated when a notch ligand binds to a receptor on an adjacent cell, also...
2.3K
Notch Signaling Pathway03:14

Notch Signaling Pathway

The Notch signaling pathway is a major intracellular signaling pathway that is highly conserved over a broad spectrum of metazoan species. It stands unique from other intracellular signaling mechanisms in animals because notch protein itself acts as the receptor as well as the primary signaling molecule.
The Notch gene came into the limelight in 1914 after the discovery that its mutation in Drosophila melanogaster leads to a serrated (or "notched") wing margin phenotype. It was not...
4.8K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.1K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
10.3K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
4.7K